PrecisionLife SVP Healthcare & Head of US Operations, Simon Beaulah, is attending and presenting at Bio-IT World Conference & Expo, building a global network for precision medicine.
Simon will be presenting in the AI for Drug Discovery and Development track on 17 May at 3.40pm.
Outside of cancer and rare disease, the impact of genomic medicine has been lower than it was originally hoped, limited the potential for precision medicine in more complex chronic diseases which account for 85% of all healthcare costs.
PrecisionLife is uncovering the biological drivers of complex chronic disease to stratify patient populations at an unprecedented resolution. This is enabling patient-focused precision drug discovery with novel drug targets and a pipeline of repositioning opportunities at all stages of development, to deliver a new age of better, more personalize treatment options.
Our precision medicine approach offers an accurate and scalable route to map effective drugs and targets to patient subgroups who will benefit from them across multiple new disease indications, providing a faster, cheaper and derisked route to their approval.
Connect with Simon at Bio-IT World or contact us to find out more about PrecisionLife.